Compugen (CGEN) Receiving Somewhat Negative Press Coverage, Analysis Shows

Media stories about Compugen (NASDAQ:CGEN) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a news sentiment score of -0.02 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5775573789223 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Compugen (NASDAQ:CGEN) opened at $2.55 on Tuesday. The company has a market cap of $132.67, a price-to-earnings ratio of -3.59 and a beta of 0.57. Compugen has a 1 year low of $2.25 and a 1 year high of $5.40.

A number of equities analysts have recently weighed in on CGEN shares. Zacks Investment Research raised shares of Compugen from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. ValuEngine downgraded shares of Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Insider Buying and Selling by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit